Patents by Inventor Conrad Gerald Chapman

Conrad Gerald Chapman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel compounds
    Publication number: 20030064481
    Abstract: A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
    Type: Application
    Filed: January 16, 2002
    Publication date: April 3, 2003
    Applicant: SmithKline Beecham Corporation and SmithKline Beecham p.l.c.
    Inventors: Michael Joseph Browne, Peter Ronald Young, Allan Richard Shatzman, Kay Elizabeth Murphy, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard
  • Neurotransmitter transporter SC6
    Patent number: 6426405
    Abstract: The SC6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SC6 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Anthony M Brown, Conrad Gerald Chapman, Israel Simon Gloger, Joanne Rachel Evans, William Cairns, Hugh Jonathan Herdon
  • Polynucleotides encoding a human potassium channel
    Patent number: 6426197
    Abstract: h-TRAAK polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing h-TRAAK polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham, P.L.C.
    Inventors: David Malcolm Duckworth, Conrad Gerald Chapman
  • Chimeric leptin fused to immunoglobulin domain and use
    Publication number: 20020058311
    Abstract: Chimeric leptin which are proteins comprising leptin or a mutant or a variant thereof fused to a human immunogobulin domain. One favoured immunoglobulin domain is the human immunoglobulin Fc domain. The chimeric derivatives of leptin have, despite their large molecular size, good pharmacological activity combined with prolonged clearance rates. These derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity or diseases and conditions associated with obesity such as atherosclerosis, hypertension and type II diabetes.
    Type: Application
    Filed: May 17, 2001
    Publication date: May 16, 2002
    Inventors: Michael Jospeh Browne, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard, Jeffery Hugh Robinson
  • Novel compounds
    Publication number: 20020028485
    Abstract: h-TREK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing h-TREK1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Application
    Filed: April 9, 2001
    Publication date: March 7, 2002
    Inventors: Helen Jane Meadows, Conrad Gerald Chapman
  • Neurotransmitter transporter SC6
    Publication number: 20010012627
    Abstract: The SC6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SC6 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Application
    Filed: February 28, 2001
    Publication date: August 9, 2001
    Inventors: Anthony M. Brown, Conrad Gerald Chapman, Israel Simon Gloger, Joanne Rachel Evans, William Cairns, Hugh Jonathan Herdon
  • h-TREK1 polypeptides and h-TREK1 polynucleotides
    Patent number: 6242217
    Abstract: h-TREK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing h-TREK1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: June 5, 2001
    Assignee: SmithKline Beecham plc
    Inventors: Helen Jane Meadows, Conrad Gerald Chapman
  • Neurotransmitter transporter SC6
    Patent number: 6238883
    Abstract: The SC6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SC6 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: May 29, 2001
    Assignee: SmithKline Beecham plc
    Inventors: Anthony M Brown, Conrad Gerald Chapman, Israel Simon Gloger, Joanne Rachel Evans, William Cairns, Hugh Jonathan Herdon
  • Compounds
    Patent number: 6180384
    Abstract: METPRO02 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing METPRO02 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: January 30, 2001
    Assignee: SmithKline Beecham plc
    Inventors: Christopher Donald Southan, Nicola Anne Burgess, Conrad Gerald Chapman
  • Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
    Patent number: 5783181
    Abstract: A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 21, 1998
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Michael Joseph Browne, Peter Ronald Young, Allan Richard Shatzman, Kay Elizabeth Murphy, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard